person · Reporting owner
Klinger Shannon Thyme
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Moderna, Inc.MRNA · Entity 2025 | Chief Legal Officer | September 04, 2026 | September 08, 2026 |
| Rafael Holdings, Inc.RFL · Entity 6620 | Director | January 05, 2022 | January 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Moderna, Inc.
Report date September 04, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,340 |
Ending reported balance
After 2026-09-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-04 · Exercise / conversion · Acquired 11,797 · Balance 87,044 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2026-09-04 · Tax withholding · Disposed 5,704 · Balance 81,340 F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 106,179 |
Reported balance
After 2026-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-04 · Exercise / conversion · Disposed 11,797 · Balance 106,179 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3: 25% of the shares subject to this restricted stock unit award vested on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter.
Rafael Holdings, Inc.
Report date January 05, 2022 · Filed January 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 5,412 |
Reported balance
After 2022-01-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-01-05 · Grant · Acquired 5,412 · Balance 5,412 F1: Grant of Restricted Stock that vests in full immediately. F2: Represents the average closing price of the Issuer's Class B common stock during December 2021. F3: Consists of fully vested shares of Restricted Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock that vests in full immediately.
F2: Represents the average closing price of the Issuer's Class B common stock during December 2021.
F3: Consists of fully vested shares of Restricted Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2025 Filed Feb 28, 2025 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 1,496 | $33.58 | $50,235.68 |
DisclosureSEC source: 0001127602-25-007265 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,365 F3 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:25 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 3,094 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-007265 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. F2 · balance_after: Includes 342 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on December 13, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Tax withholdingCommon Stock | 1,068 | $30.93 | $33,033.24 |
DisclosureSEC source: 0001127602-25-004913 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,425 F2 · kind: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vesting of the 2022 PSUs. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:15 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantCommon Stock | 2,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004913 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,493 F1 · kind: The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 1, 2022 (the "2022 PSUs"). Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 529 | $44.68 | $23,637.31 |
DisclosureSEC source: 0001127602-24-028963 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,446 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028963 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,278 Underlying: Common Stock · 1,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:08 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028963 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:51 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 188,761 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028774 · form4.xml · derivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,761 Underlying: Common Stock · 188,761 shares Expires not disclosed F1 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award will vest on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. F1 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award will vest on December 5, 2025, with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 112 | $43.30 | $4,849.28 |
DisclosureSEC source: 0001127602-24-028668 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,837 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028668 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,164 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028668 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,418 | $42.79 | $60,674.94 |
DisclosureSEC source: 0001127602-24-028297 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,717 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028297 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,653 Underlying: Common Stock · 2,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F4 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028297 · form4.xml · derivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,959 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028297 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:19 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-028297 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 551 | $73.57 | $40,538.78 |
DisclosureSEC source: 0001127602-24-023704 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,154 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023704 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,416 Underlying: Common Stock · 1,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:15 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023704 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 21:42 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 114 | $76.99 | $8,776.75 |
DisclosureSEC source: 0001127602-24-023427 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,566 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 21:42 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023427 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,396 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 21:42 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023427 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 162 | $78.03 | $12,640.21 |
DisclosureSEC source: 0001127602-24-023237 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,447 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,319 | $79.39 | $104,721.87 |
DisclosureSEC source: 0001127602-24-023134 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,280 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023237 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,288 Underlying: Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| August 28, 2024 Filed Aug 30, 2024 20:34 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023237 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023134 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,305 Underlying: Common Stock · 2,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 20:03 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-023134 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 5,178 | $148.09 | $766,784.65 |
DisclosureSEC source: 0001127602-24-018351 · form4.xml · nonDerivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,947 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 9,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018351 · form4.xml · derivative · entry 5 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: 100% of the shares subject to this restricted stock unit award vested on June 7, 2024. F4 · derivative.expiration_date: 100% of the shares subject to this restricted stock unit award vested on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018351 · form4.xml · derivative · entry 4 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,555 Underlying: Common Stock · 1,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 9,108 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018351 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,139 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018351 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 122 | $140.72 | $17,167.82 |
DisclosureSEC source: 0001127602-24-017742 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,878 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017742 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,629 Underlying: Common Stock · 232 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017742 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 29, 2024 Filed May 30, 2024 20:27 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 183 | $144.50 | $26,444.36 |
DisclosureSEC source: 0001127602-24-016975 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,768 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 28, 2024 Filed May 29, 2024 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 1,296 | $162.47 | $210,565.79 |
DisclosureSEC source: 0001127602-24-016773 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,623 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 328 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016975 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,617 Underlying: Common Stock · 328 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 28, 2024 Filed May 30, 2024 20:27 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 328 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016975 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 2,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-016773 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,957 Underlying: Common Stock · 2,652 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter. Read SEC document |
| May 24, 2024 Filed May 29, 2024 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 2,652 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016773 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 13:05 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 544 | $99.05 | $53,883.69 |
DisclosureSEC source: 0001127602-24-009302 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,267 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 13:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009302 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,694 Underlying: Common Stock · 1,138 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 13:05 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 1,138 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-009302 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 22:56 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 117 | $94.34 | $11,037.58 |
DisclosureSEC source: 0001127602-24-008675 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,673 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 233 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-008675 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,861 Underlying: Common Stock · 233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 22:56 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 233 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-008675 · form4.xml · nonDerivative · entry 1 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 22:29 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 670 | $94.57 | $63,363.24 |
DisclosureSEC source: 0001127602-24-007941 · form4.xml · nonDerivative · entry 2 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,557 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 22:29 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 1,315 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007941 · form4.xml · derivative · entry 3 Klinger Shannon Thyme · CIK 0001866132 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,945 Underlying: Common Stock · 1,315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. F3 · derivative.expiration_date: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.